Jci_page_head_homepage_01 Jci_page_head_homepage_02
Robert C. Gensure, Outi Mäkitie, Catherine Barclay, Catherine Chan, Steven R. DePalma, Murat Bastepe, Hilal Abuzahra, Richard Couper, Stefan Mundlos, David Sillence, Leena Ala Kokko, Jonathan G. Seidman, William G. Cole, Harald Jüppner
Published in Volume 115, Issue 5
J Clin Invest. 2005; 115(5):1250–1257 doi:10.1172/JCI22760
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 3

Nucleotide sequence analysis of portions of exon 41 of COL1A1 and adjacent intronic regions of an affected individual from family 1. The individual was heterozygous for the transition, which is indicated by the arrow, and the approximate location of both primers for PCR amplification is indicated by arrowheads within the schematic, partial drawing of COL1A1. Partial nucleotide sequence of wild-type and mutant (mut) exon 41 (capital letters), as well as adjacent intronic sequence (lower-case letters), along with the encoded amino acid sequence, are shown. The 3040C↠T transition (indicated by an asterisk), which alters the first nucleotide of the second-to-last codon in exon 41, is predicted to result in the substitution of an arginine (R) 836 to a cysteine (C) residue (R836C). The approximate location of the R836C mutation within the triple-helical region of the collagen fibril is schematically shown [bottom: thin lines, α1(I) chains; thick line, α2(I) chain], as is the location of the R134C mutation previously described in 2 unrelated patients with Ehlers-Danlos syndrome type I (31).